According to Acumen Research and Consulting, the global chondroitin sulfate market size is anticipated to worth around US$ 1.5 billion by 2026 and growing at a CAGR of 3.3 % over the forecast time period 2019 to 2026.
Chondroitin sulfate is also regarded as glycosaminoglycan sulfated glucose (GAG). Chondroitin sulfate comprises a large alternating sugar chain including glucuronic acid and N-acetylgalactosamine. Chondroitin sulfate is a chemical compound discovered in human connective tissues in cartilage and in human joints. Commercial chondroitin sulfate is produced from different animal sources, including pork, bovine, chicken, fish, shark, crocodiles, etc. Chondroitin sulfate is used to stop the growth of osteoarthritis as an alternative medicine. Chondroitin sulphate also helps to decrease pain and inflammation in the articulation. Regular chondroitin sulfate intake contributes to enhanced joint activities. Commercial chondroitin is a glucosamine and chondroitin sulfate combination. Chondroitin sulfate can be used, in addition to enhancing joint function, as an eye fall for waxing teeth, in addition to veterinary use.
The report provides analysis of global Chondroitin Sulfate market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
In addition to the incidence of osteoarthritis, increased demand for nutraceuticals will fuel market growth over the forecast period. Chondroitin sulfate is mainly used for treating osteoarthritis, cataracts and urinary tract infections, which are expected to increase overall product demand during the forecast period. It is also used to improve digestive function, improve the function of the liver, reduce blood sugar and prevent tumor metastasis.
The use of sodium chondroitin sulfate as thickeners, additives, foaming agents, preservatives and hygiene foods in dietary supplements and meat products. It is in animal feed because of its ability to treat joint pain and arthritis such as chronic pain and dolors of arthritis, elbow dysplasia and hip dysplasia in animals. It is also used in animal feed. The use of the item in meal grade and meal grade apps is expected to show quicker development in the near future compared to standard forms.
It has seen a elevated level of acceptance in developed economies like Germany, the United Kingdom and the United States relative to other emerging economies worldwide. This can be linked to the elevated incidence of osteoarthritis among consumers in the nations, favourable laws and advanced health infrastructure. Increasing R&D operations in advanced countries are expected to boost demand over the prediction era to enhance performance and decrease operating expenses.
In 2018, Bovine was the dominant source category because it is used for multiple purposes including nutraceuticals, pharmaceuticals and animal feed. Bovine cartilage is a large scale by-product of the beef industry around the world. Cattle byproducts are already used in multiple areas of the globe for human consumption. These variables have led producers to choose bovine as a source of sodium chondroitin sulfate.
In the pharmaceutical industry, shark-derived chondroitin is chosen for its capacity to cure arthritis, eye problems and healing wounds. Sharks are listed as endangered species and this element can be a restrictive variable in the development of the industry in chondroitin sulfate. However, the capacity of shark-borne sodium chondroitin sulfate to handle individuals infected with HIV, tuberculosis and swelling of the intestine, which are supposed to further boost demand through the forecast period, is preferable.
Synthetic chondroitin is produced with a two-stage fermentation method. The method excludes the use of animal cartilage to reduce contamination and adulteration. Furthermore, the method of extraction is less complex and therefore small manufacturing costs. In the Asian and the Middle East nations, demand for synthetic chondroitin is anticipated to expand because the item is not of animal origin and, therefore, an option to vegetarian populations with cultural and nutritional constraints.
Sodium chondroitin Sulfate is commonly used as a dietary supplement to treat osteoarthritis and articular pain in the nutraceutical sector. The supplements are used to relieve arthritis pain and reinforce joint, cartilage and bones. In the United States, it is marketed as a nutritional aid to cure arthritis suffering and supplied with glucosamine. The increased consumption of nutritional supplements in developed economies like the USA is expected to boost development in the sector. It is marketed under the European Medicines Agency as a prescription drug. Another request involves entry into the urinary tract (UTI) blood, bladder circumstances, or bladder control loss. Increased consumption of sodium chondroitin sulfate in pharmaceutical apps is expected to fuel chondroitin to cure cardiac diseases, use as eye drops and alleviate joint pain and arthritis.
The chemical is also used as thickener, foaming agent and preservative in meal preparations. It is used in food apps such as drinks, chewing gums and dairy products. Advantageous public laws regarding consumer consumption as a food additive should fuel market growth over the forecast period.
The largest regional market in North America was estimated to be about USD 400 million in 2018. The booming pharmaceutical industry in the U.S. and FDA approval for sodium chondroitin sulfate infusers can be attributed to industry growth in the region. The demands are expected to be driven by factors such as the high prevalence of osteoarthritis and increased use of cholesterol in cataract surgery and formulations for a drop in the eye.
In 2003, the European League Against Rheumatism (EULAR) board ranked its toxicity level at 0-100 at the 6th position. Sodium chondroitin sulfate is used in several EU nations in the pharmaceutical industry, including Switzerland, Italy, Austria, Greece, Portugal, France and the East. Asia Pacific is estimated to be the fastest growing country with a 3.4% CAGR over the prediction era due to elevated osteoarthritis incidence and increasing customer knowledge of nutritional supplements. With the development in the region of the end-user industries, including nutraceutical, pharmaceutical, personal care and cosmetics, Asia Pacific was the second largest regional market in 2018. Increased product production in the area and increased exports from key countries such as China and Japan are expected to contribute to the growth of this industry.
Global Chondroitin Sulfate Market, by Source
Global Chondroitin Sulfate Market, by Application
Global Chondroitin Sulfate Market, by Geography
The market research study on “Chondroitin Sulfate Market Size, Share & Trends Analysis Report by Source, Application, and Region - Global Industry Size, Share, Trends and Forecast 2019 - 2026” offers detailed insights on global Chondroitin Sulfate market segments with market dynamics and their impact. The report also covers basic technology development policies.
Key Players & Strategies
Major players included in this report are Bioiberica S.A.U.; Qingdao Wan tulmin Biological Products Co. Ltd.; Sigma-Aldrich, Inc.; HeBei SanXin Industrial Group; Sino Siam Biotechnique Company Limited; Bio-gen Extracts Private Limited; TSI Group Ltd.; ZPD; and SEIKAGAKU CORPORATION.
Key developed economies producers such as the US, France, Germany and the UK. The majority supply to important actors in the nutraceutical and pharmaceutical industries of sodium chondroitin sulfate. The development of osteoarthritis and rising consumption of dietary supplements can be ascribed to this industry.
Due to the existence of a big amount of producers, particularly in China, the industry is extremely divided in nature. Competitive business competition is strong due to increased R&D investments in product development and increased consumer effectiveness. High competition in product final rates and the concentrate on the use of natural ingredients by producers thus denotes elevated market rivalry.